NASDAQ · DNTH
Dianthus Therapeutics, Inc.
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
Loading market information…
NYSE · CTEV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 67.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Claritev Corporation’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$3.63. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Claritev Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:52 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$4.38-99.09% vs estimate | $231.33M+0.89% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | -$8.82+10.09% vs estimate | $232.10M-0.96% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$24.25-782.87% vs estimate | $230.50M-1.36% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $43.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
$49.63+$0.38 (+0.77%)
AxoGen, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.2% below the high.
$1.66+$0.04 (+2.47%)
OPKO Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.21% below the high.
$3.54+$0.07 (+2.02%)
GoodRx Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.0% below the high.
$85.74+$1.81 (+2.16%)
IRadimed Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.54% below the high.
$12.83+$0.59 (+4.82%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$2.72+$0.09 (+3.42%)
Sana Biotechnology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.99% below the high.
$13.51+$0.14 (+1.05%)
InMode Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.96% below the high.
